CN114617916B - 一种枇杷叶提取物及其在康养方面中的应用 - Google Patents
一种枇杷叶提取物及其在康养方面中的应用 Download PDFInfo
- Publication number
- CN114617916B CN114617916B CN202210409014.3A CN202210409014A CN114617916B CN 114617916 B CN114617916 B CN 114617916B CN 202210409014 A CN202210409014 A CN 202210409014A CN 114617916 B CN114617916 B CN 114617916B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- loquat leaf
- leaf extract
- petroleum ether
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 58
- 235000009008 Eriobotrya japonica Nutrition 0.000 title claims abstract description 56
- 230000036541 health Effects 0.000 title abstract description 8
- 244000061508 Eriobotrya japonica Species 0.000 title description 2
- 241001092070 Eriobotrya Species 0.000 claims abstract description 55
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229940045997 vitamin a Drugs 0.000 claims abstract description 46
- 239000000243 solution Substances 0.000 claims abstract description 38
- 239000003208 petroleum Substances 0.000 claims abstract description 33
- 238000010521 absorption reaction Methods 0.000 claims abstract description 19
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- 239000012259 ether extract Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 208000010011 Vitamin A Deficiency Diseases 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000001737 promoting effect Effects 0.000 claims description 10
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 8
- 208000001140 Night Blindness Diseases 0.000 claims description 8
- 206010013774 Dry eye Diseases 0.000 claims description 7
- 206010013786 Dry skin Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000037336 dry skin Effects 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract description 30
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract description 30
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract description 30
- 235000019155 vitamin A Nutrition 0.000 abstract description 30
- 239000011719 vitamin A Substances 0.000 abstract description 30
- 239000000203 mixture Substances 0.000 description 57
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 38
- 229930003427 Vitamin E Natural products 0.000 description 19
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 19
- 235000019165 vitamin E Nutrition 0.000 description 19
- 229940046009 vitamin E Drugs 0.000 description 19
- 239000011709 vitamin E Substances 0.000 description 19
- 238000009472 formulation Methods 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- -1 nyctalopia Chemical compound 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000004300 dark adaptation Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种枇杷叶提取物及其在康养方面中的应用。具体地,本发明提供一种枇杷叶提取物,所述的枇杷叶提取物通过以下方法制备:(i)将枇杷叶用乙醇水溶液提取,得到的提取液浓缩后,得到浓缩水溶液;(ii)用石油醚对所述浓缩水溶液进行萃取,得到的石油醚萃取液减压浓缩除去石油醚后,得到枇杷叶提取物。本发明所述的枇杷叶提取物能够显著促进维生素A口服吸收。
Description
技术领域
本发明涉及药物领域,具体涉及一种枇杷叶提取物及其在康养方面中的应用。
背景技术
维生素A有促进生长、繁殖,维持骨骼、上皮组织、视力和粘膜上皮正常分泌等多种生理功能,维生素A及其类似物有阻止癌前期病变的作用。缺乏时表现为生长迟缓、暗适应能力减退而形成夜盲症,表皮和粘膜上皮细胞干燥、脱屑、过度角化、泪腺分泌减少,从而发生干眼病,重者角膜软化、穿孔而失明。呼吸道上皮细胞角化并失去纤毛,使抵抗力降低易于感染。
老年人由于消化功能的减弱,胃的消化能力在退化,胃肠道功能减弱导致对维生素A的口服吸收减弱,对维生素A的摄入量降低,容易出现维生素A缺乏症如夜盲症、眼睛干涩和皮肤干燥等等,而现有临床中缺乏一种对维生素A进行有效促进吸收的药物,从而限制了老年人的康复。
因此,本领域需要开发一种促进维生素A口服吸收的药物。
发明内容
本发明的目的在于提供一种促进维生素A口服吸收枇杷叶提取物,从而促进维生素A的口服吸收。
本发明第一个方面提供一种枇杷叶提取物,所述的枇杷叶提取物通过以下方法制备:
(i)将枇杷叶用乙醇水溶液提取,得到的提取液浓缩后,得到浓缩水溶液;
(ii)用石油醚对所述浓缩水溶液进行萃取,得到的石油醚萃取液减压浓缩除去石油醚后,得到枇杷叶提取物。
优选地,所述乙醇水溶液中,乙醇的体积分数为50-70%,优选为55-65%,优选为60%。
优选地,所述的枇杷叶提取物通过以下方法制备:
(i)将枇杷叶用6-7重量倍的体积分数为55-65%乙醇水溶液加热回流提取4.5-5.5h,得到的提取液浓缩后,得到浓缩水溶液;
(ii)用石油醚对所述浓缩水溶液进行萃取,得到的石油醚萃取液减压浓缩除去石油醚后,得到枇杷叶提取物。
优选地,所述的枇杷叶提取物通过以下方法制备:
将枇杷叶78-82g加入到480-520ml体积分数为58-62%的乙醇水溶液中,加热回流提取4.8-5.2h,过滤,得到的滤液经减压浓缩,得到140-160ml浓缩液,向140-160ml浓缩液中加入480-520ml石油醚,萃取,分离石油醚层萃取液,石油醚层萃取液经减压浓缩除去石油醚后,干燥,得到枇杷叶提取物。
本发明第二个方面提供一种如本发明第一个方面所述的枇杷叶提取物的用途,用于制备组合物,所述的组合物用于选自下组的一种或多种用途:(1)促进维生素A的口服吸收;(2)治疗维生素A缺乏症;和/或(3)预防和/或治疗与维生素A缺乏相关的疾病。
优选地,所述的组合物的剂型为固体制剂或液体制剂。
优选地,所述的组合物的剂型为口服制剂或注射制剂。
优选地,所述的组合物的剂型为口服液、混悬液、片剂或胶囊剂。
优选地,所述的组合物为药物组合物、食品组合物或保健品组合物。
优选地,所述的组合物还包括药学上、食品上或保健品上可接受的载体。
优选地,所述缺乏包括血液、血清或血浆缺乏。
优选地,所述的与维生素A缺乏相关的疾病包括夜盲症、眼睛干涩和/或皮肤干燥。
优选地,所述的组合物还包括维生素A。
优选地,所述的组合物还包括维生素E。
优选地,所述的组合物还包括维生素A和维生素E。
优选地,所述的枇杷叶提取物与所述维生素E的重量比为(1-15):1,优选为(2-10):1,优选为(3-7):1,优选为(4-6):1,优选为5:1。
优选地,所述的枇杷叶提取物与所述维生素A的重量比为(1-15):1,优选为(2-10):1,优选为(3-7):1,优选为(4-6):1,优选为5:1。
本发明第三个方面提供一种组合物,所述的组合物包括如本发明第一方面所述的枇杷叶提取物和维生素E。
优选地,所述的枇杷叶提取物与所述维生素E的重量比为(1-15):1,优选为(2-10):1,优选为(3-7):1,优选为(4-6):1,优选为5:1。
优选地,所述的组合物还包括维生素A。
优选地,所述的枇杷叶提取物与所述维生素A的重量比为(1-15):1,优选为(2-10):1,优选为(3-7):1,优选为(4-6):1,优选为5:1。
优选地,所述的组合物的剂型为固体制剂或液体制剂。
优选地,所述的组合物的剂型为口服制剂或注射制剂。
优选地,所述的组合物的剂型为口服液、混悬液、片剂或胶囊剂。
优选地,所述的组合物为药物组合物、食品组合物或保健品组合物。
优选地,所述的组合物还包括药学上、食品上或保健品上可接受的载体。
优选地,所述的枇杷叶提取物的含量为1-99wt%,较佳地10-90wt%,更佳地20-80wt%,以组合物的总重量计算。
优选地,所述的维生素E的含量为1-99wt%,较佳地10-90wt%,更佳地20-80wt%,以组合物的总重量计算。
本发明第四个方面提供一种本发明第三个方面所述的组合物的用途,用于制备制剂,所述的制剂用于选自下组的一种或多种用途:
(1)促进维生素A的口服吸收;(2)治疗维生素A缺乏症;和/或(3)预防和/或治疗与维生素A缺乏相关的疾病。
优选地,所述的制剂的剂型为固体制剂或液体制剂。
优选地,所述的制剂的剂型为口服制剂或注射制剂。
优选地,所述的制剂的剂型为口服液、混悬液、片剂或胶囊剂。
优选地,所述的制剂为药物组合物、食品组合物或保健品组合物。
优选地,所述的制剂包括药学上、食品上或保健品上可接受的载体。
优选地,所述维生素A缺乏包括血液、血清或血浆缺乏。
优选地,所述的与维生素A缺乏相关的疾病包括夜盲症、眼睛干涩和/或皮肤干燥。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。
具体实施方式
本发明开发了一种枇杷叶提取物,所述的枇杷叶提取物能够显著促进维生素A的口服吸收。
术语
除非另有定义,否则本文中所用的所有技术和科学术语的含义与本发明所属领域普通技术人员普遍理解的含义相同。
如本文所用,术语“包括”、“包含”与“含有”可互换使用,不仅包括开放式定义,还包括半封闭式、和封闭式定义。换言之,所述术语包括了“由……构成”、“基本上由……构成”。
如本文所用,术语“体积分数为58-62%的乙醇水溶液”是指在乙醇水溶液中,乙醇的体积百分比为58-62%。例如,体积分数为60%的乙醇水溶液可以通过将40ml水和60ml乙醇混合制备得到。
如本文所用,术语“枇杷叶”为蔷薇科植物枇杷Eriobotrya japonica(Thunb.)Lindl.的干燥叶。
如本文所用,术语“维生素A”英文为Vitamin A。
如本文所用,术语“维生素E”英文为Vitamin E。
在本发明中,术语“预防”表示预防疾病和/或它的附随症状的发作或者保护对象免于获得疾病的方法。
在本发明中,术语“治疗”包括延缓和终止疾病的进展,或消除疾病。
枇杷叶提取物
本发明提供一种枇杷叶提取物,所述的枇杷叶提取物通过以下方法制备:
(i)将枇杷叶用乙醇水溶液提取,得到的提取液浓缩后,得到浓缩水溶液;
(ii)用石油醚对所述浓缩水溶液进行萃取,得到的石油醚萃取液减压浓缩除去石油醚后,得到枇杷叶提取物。
优选地,所述乙醇水溶液中,乙醇的体积分数为50-70%,优选为55-65%,优选为60%。
在本发明的一个优选例中,所述的枇杷叶提取物通过以下方法制备:
(i)将枇杷叶用6-7重量倍的体积分数为55-65%乙醇水溶液加热回流提取4.5-5.5h,得到的提取液浓缩后,得到浓缩水溶液;
(ii)用石油醚对所述浓缩水溶液进行萃取,得到的石油醚萃取液减压浓缩除去石油醚后,得到枇杷叶提取物。
优选地,所述的枇杷叶提取物通过以下方法制备:
将枇杷叶78-82g加入到480-520ml体积分数为58-62%的乙醇水溶液中,加热回流提取4.8-5.2h,过滤,得到的滤液经减压浓缩,得到140-160ml浓缩液,向140-160ml浓缩液中加入480-520ml石油醚,萃取,分离石油醚层萃取液,石油醚层萃取液经减压浓缩除去石油醚后,干燥,得到枇杷叶提取物。
用途
本发明提供一种如本发明所述的枇杷叶提取物的用途,用于制备组合物,所述的组合物用于选自下组的一种或多种用途:(1)促进维生素A的口服吸收;(2)治疗维生素A缺乏症;和/或(3)预防和/或治疗与维生素A缺乏相关的疾病。
在本发明的一个优选例中,所述缺乏包括血液、血清或血浆缺乏。
在本发明的一个优选例中,所述的与维生素A缺乏相关的疾病包括夜盲症、眼睛干涩和/或皮肤干燥。
在本发明的一个优选例中,所述的组合物还包括维生素A。
在本发明的一个优选例中,所述的组合物还包括维生素E。
在本发明的一个优选例中,所述的组合物还包括维生素A和维生素E。
优选地,所述的枇杷叶提取物与所述维生素E的重量比为(1-15):1,优选为(2-10):1,优选为(3-7):1,优选为(4-6):1,优选为5:1。
优选地,所述的枇杷叶提取物与所述维生素A的重量比为(1-15):1,优选为(2-10):1,优选为(3-7):1,优选为(4-6):1,优选为5:1。
组合物
本发明还提供一种组合物,所述的组合物包括本发明所述的枇杷叶提取物和维生素E。
优选地,所述的枇杷叶提取物与所述维生素E的重量比为(1-15):1,优选为(2-10):1,优选为(3-7):1,优选为(4-6):1,优选为5:1。
选地,所述的组合物还包括维生素A。
优选地,所述的枇杷叶提取物与所述维生素A的重量比为(1-15):1,优选为(2-10):1,优选为(3-7):1,优选为(4-6):1,优选为5:1。
优在本发明的一个优选例中,所述的枇杷叶提取物的含量为1-99wt%,较佳地10-90wt%,更佳地20-80wt%,以组合物的总重量计算。
在本发明的一个优选例中,所述的维生素E的含量为1-99wt%,较佳地10-90wt%,更佳地20-80wt%,以组合物的总重量计算。
在本发明的一个优选例中,所述的维生素A的含量为1-99wt%,较佳地10-90wt%,更佳地20-80wt%,以组合物的总重量计算。
在本发明的一个优选例中,所述的组合物的剂型为固体制剂或液体制剂。
在本发明的一个优选例中,所述的组合物的剂型为口服制剂或注射制剂。
优选地,所述的组合物的剂型为口服液、混悬液、片剂或胶囊剂。
在本发明的一个优选例中,所述的组合物为药物组合物、食品组合物或保健品组合物。
优选地,所述的组合物还包括药学上、食品上或保健品上可接受的载体。
如本文所用“药学上、食品上或保健品上可接受的载体”是指一种或多种相容性固体、半固体、液体或凝胶填料,它们适合于人体或动物使用,而且必须有足够的纯度和足够低的毒性。“相容性”是指药物组合物中的各组分和药物的活性成分以及它们之间相互掺和,而不明显降低药效。
应理解,在本发明中,所述的药学上、食品上或保健品上可接受的载体没有特别的限制,可选用本领域常用材料,或用常规方法制得,或从市场购买得到。药学可接受的载体部分例子有纤维素及其衍生物(如甲基纤维素、乙基纤维素、羟丙甲基纤维素、羧甲基纤维素钠等)、明胶、滑石粉、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油、等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如吐温)、润湿剂(如十二烷基硫酸钠)、缓冲剂、螯合剂、增稠剂、pH调节剂、透皮促进剂、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、抑菌剂、无热原水等。
本发明的主要技术效果包括:
本发明开发了一种枇杷叶提取物,所述的枇杷叶提取物能够显著促进维生素A的口服吸收,提高对维生素A缺乏症如夜盲症、眼睛干涩和皮肤干燥等等治疗效果,从而对维生素A吸收减弱的患者如老年人具有优异的康养效果。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。
实施例1
本实施例考察枇杷叶提取物在促进维生素A口服吸收效果
1.枇杷叶提取物的制备方法如下:
将粉碎后的枇杷叶80g加入到500ml体积分数为60%的乙醇水溶液中,加热回流提取5h,过滤,得到的滤液经减压浓缩,得到150ml浓缩液,向150ml浓缩液中加入500ml石油醚,萃取,分离石油醚层萃取液,石油醚层萃取液经减压浓缩除去石油醚后,干燥,得到枇杷叶提取物。
2.考察促进维生素A口服吸收效果
考察本实施例制备的枇杷叶提取物对维生素A口服吸收的促进作用,实验方法如下:
将SPF级KM雄性小鼠前一天晚21:00后禁食不禁水,第二天早上8:00随机分成5组,每组10只,各组的给药方式如下:
对照组:灌胃给予生理盐水;
实验组1:灌胃给予维生素A,维生素A的给药剂量为1mg/kg.bw;
实验组2:灌胃给予维生素A和实施例1制备的枇杷叶提取物,维生素A的给药剂量为1mg/kg.bw,实施例1制备的枇杷叶提取物10mg/kg.bw;
实验组3:灌胃给予维生素A和维生素E,维生素A的给药剂量为1mg/kg.bw,维生素E的给药剂量为2mg/kg.bw;
实验组4:灌胃给予维生素A、维生素E和实施例1制备的枇杷叶提取物,维生素A的给药剂量为1mg/kg.bw,维生素E的给药剂量为1mg/kg.bw和实施例1制备的枇杷叶提取物5mg/kg.bw
各组药物用生理盐水分散后进行灌胃,各组小鼠每天灌胃给药1次,连续灌胃给药10天,实验期间,各组小鼠用普通饲料进行饲养,自由饮水,测定给药10天后的小鼠血清维生素A的含量。
采用维生素A酶联免疫分析检测试剂盒,测定小鼠血清中的维生素A含量,各组小鼠给药10天后的小鼠血清维生素A的含量下表1所示:
表1各组小鼠给药10天后血清维生素A含量(M±SD)
从表1可以看出,本实施例1制备的枇杷叶提取物能够促进维生素A的口服吸收,从而能够有效低预防和治疗高维生素A缺乏症,且本实施例1制备的枇杷叶提取物和维生素E在促进维生素A的口服吸收方面具有协同效果,从而能够显著促进维生素A的口服吸收,预防和治疗高维生素A缺乏症如夜盲症、眼睛干涩和皮肤干燥等等。
以上所述仅为本申请的优选实施例而已,并不用于限制本申请,对于本领域的技术人员来说,本申请可以有各种更改和变化。凡在本申请的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本申请的保护范围之内。
Claims (4)
1.一种枇杷叶提取物在制备药物中的用途,其特征在于,所述的药物用于(1)促进维生素A的口服吸收;和/或(2)治疗维生素A缺乏症;
所述的枇杷叶提取物通过以下方法制备:
(i)将枇杷叶用乙醇水溶液提取,得到的提取液浓缩后,得到浓缩水溶液,其中,所述乙醇水溶液中,乙醇的体积分数为55-65%;
(ii)用石油醚对所述浓缩水溶液进行萃取,得到的石油醚萃取液减压浓缩除去石油醚后,得到枇杷叶提取物。
2.如权利要求1所述的用途,其特征在于,所述的枇杷叶提取物通过以下方法制备:
(i)将枇杷叶用6-7重量倍的体积分数为55-65%乙醇水溶液加热回流提取4.5-5.5h,得到的提取液浓缩后,得到浓缩水溶液;
(ii)用石油醚对所述浓缩水溶液进行萃取,得到的石油醚萃取液减压浓缩除去石油醚后,得到枇杷叶提取物。
3.如权利要求1所述的用途,其特征在于,所述乙醇水溶液中,乙醇的体积分数为60%。
4.如权利要求1所述的用途,其特征在于,所述的维生素A缺乏症包括夜盲症、眼睛干涩和/或皮肤干燥。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210409014.3A CN114617916B (zh) | 2022-04-19 | 2022-04-19 | 一种枇杷叶提取物及其在康养方面中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210409014.3A CN114617916B (zh) | 2022-04-19 | 2022-04-19 | 一种枇杷叶提取物及其在康养方面中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114617916A CN114617916A (zh) | 2022-06-14 |
CN114617916B true CN114617916B (zh) | 2023-09-22 |
Family
ID=81905564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210409014.3A Active CN114617916B (zh) | 2022-04-19 | 2022-04-19 | 一种枇杷叶提取物及其在康养方面中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114617916B (zh) |
-
2022
- 2022-04-19 CN CN202210409014.3A patent/CN114617916B/zh active Active
Non-Patent Citations (4)
Title |
---|
Current Status of Loquat (Eriobotrya Japonica Lindl.): Bioactive Functions, Preservation Approaches, and Processed Products;Atul Dhiman等;《Food Reviews International》;20210111;第1-31页,尤其是第1页摘要 * |
Involvement of multiple phytoene synthase genes in tissue and cultivar-specific accumulation of carotenoids in loquat;Xiumin Fu等;《Journal of Experimental Botany》;20140616;第65卷(第16期);第4679-4689页,尤其是第4682页右栏最后1段,第4683页左栏第1段及图2 * |
枇杷叶的化学成分研究(Ⅰ);陈剑等;《中草药》;20061130;第37卷(第11期);第1632-1634页,尤其是第1632页右栏第2段 * |
陈剑等.枇杷叶的化学成分研究(Ⅰ).《中草药》.2006,第37卷(第11期),第1632-1634页,尤其是第1632页右栏第2段. * |
Also Published As
Publication number | Publication date |
---|---|
CN114617916A (zh) | 2022-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5284097B2 (ja) | 抗肥満組成物 | |
JP2009511468A5 (zh) | ||
CN112915113B (zh) | 鸦胆子油乳剂在制备治疗或预防口腔溃疡的药物中的用途 | |
CN102764408A (zh) | 一种解酒制剂 | |
JP2011522844A (ja) | 血糖レベルを低下させる組成物及びその用途 | |
TW200800153A (en) | Composition for inhibiting low blood sugar syndrome | |
CN108245572B (zh) | 柑橘属果实挥发油的应用以及含柑橘属果实挥发油的药品 | |
CN114617916B (zh) | 一种枇杷叶提取物及其在康养方面中的应用 | |
CN102526619A (zh) | 一种醒脑静鼻腔喷雾剂及其制备方法和应用 | |
CN101028446A (zh) | 治疗症状性干眼的药物 | |
CN112546083A (zh) | 一种含有七叶皂苷钠的消肿镇痛复方制剂及其制备方法 | |
EP2688577B1 (de) | Zusammensetzung zur anwendung bei verdauungsbeschwerden | |
KR20050114040A (ko) | 비만 억제용 한약 조성물 및 그 제조방법 | |
EA013457B1 (ru) | Средство для лечения шума в ушах | |
CN114177160A (zh) | 一种治疗口腔溃疡的足贴及其制备方法 | |
KR20140093461A (ko) | 음용감이 우수한 소화기능 개선용 민트명수액 및 그 제조 방법 | |
EP1884241A1 (en) | A oral preparation comprising dyclonine hydrochloride | |
KR20010009653A (ko) | 성기능 장애를 위한 치료용 조성물 | |
CN108785559A (zh) | 一种治疗呼吸道感染的药物及其制备方法 | |
US3894153A (en) | Method of medical treatment of asthma | |
CN103585460B (zh) | 一种用于牙龈止血的填塞剂 | |
JPH09187248A (ja) | 抗アレルギー食品 | |
CN112353837B (zh) | 葛花提取物及其用途 | |
CN103142928A (zh) | 骨筋口服液及其制备方法 | |
CN110151922B (zh) | 用于治疗心绞痛合并高血压病的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |